SCHEMBL7455602

SCHEMBL7455602

Cc1nnc(C)n1CCO

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.41
THRB P10828 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 1/20 0.34
TDO2 P48775 1/20 0.33
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.31
HSD11B1 P28845 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9263752 0.84 MAPT (0.47) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL10388579 0.82 MAPT (0.41) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL9688348 0.76 TSHR (0.54) TSHRKMT2AHSD11B1
SCHEMBL10667972 0.70 KMT2A (0.42) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL7455961 0.69 LMNA (0.56) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL543570 0.67 ALDH1A1 (0.60) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL14446910 0.66 HSD17B10 (0.40) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL5383922 0.65 KMT2A (0.45) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL5383920 0.65 KMT2A (0.45) ALDH1A1LMNATSHRTHRBMAPK1
SCHEMBL18912379 0.62 L3MBTL1 (0.40) ALDH1A1LMNAMAPK1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6362336-B1 ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT ZENECA LIMITED (GB) 2002-03-26 US disclosed
US-20020032208-A1 Chemical compounds ZENECA LIMITED 2002-03-14 US disclosed
EP-0873319-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-07-25 EP disclosed
US-6258951-B1 ANTICANCER, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 2001-07-10 US disclosed
US-6071921-A Chemical compounds ZENECA LIMITED (GB) 2000-06-06 US disclosed
US-5962458-A ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS ZENECA LIMITED (GB) 1999-10-05 US disclosed
EP-0329357-B1 DIHYDROPYRIDINE ANTI-ALLERGIC AND ANTI-INFLAMMATORY AGENTS Pfizer Limited (GB) 1992-07-15 EP disclosed
EP-0329357-A1 Dihydropyridine anti-allergic and anti-inflammatory agents Pfizer Limited (GB) 1989-08-23 EP disclosed
US-4859686-A Dihydropyridine anti-allergic and anti-inflammatory agents PFIZER INC. (US) 1989-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032208-A1 Chemical compounds FLT1, CNKSR1, KDR ALDH1A1 2174/4885LMNA 3796/4885TSHR 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.